Clinical trial
A Randomized, Open-Label, Phase 2a Comparator Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L-Ornithine Phenylacetate) Versus Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy
NCT03712280 is registered in ClinicalTrials.gov with Mallinckrodt as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-Label, Phase 2a Comparator Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L-Ornithine Phenylacetate) Versus Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes of Hepatic Encephalopathy
- Lead sponsor
- Mallinckrodt
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 1, 2018
- Completion date
- July 14, 2020
- Enrollment
- 50 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
hepatic cirrhosis, hepatic encephalopathy (he)